语言版本

Time of issue:2021-09-02 16:56:33
搜索
Search
/
/
/
Ruxolitinib phosphate
All categories
Number of views:
1000

Ruxolitinib phosphate

Ruxolitinib phosphate is indicated for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis (PMF) (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis (PPV-MF), orpost-essential thrombocythemia myelofibrosis (PET-MF).
Retail price
0.0
Market price
0.0
Number of views:
1000
No.
Category
API
Chemical Name:
(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate
Molecular Formula:
C17H18N6·H3PO4
Molecular Weight:
404.36
Therapeutic Classification:
Oncology
CAS:
1092939-17-7
Registration File:
US-DMF
Quantity
-
+
Stock:
Detail
Parameters

  Ruxolitinib phosphate is indicated for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis (PMF) (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis (PPV-MF), orpost-essential thrombocythemia myelofibrosis (PET-MF).

Keyword:
myelofibrosis
known
Scan the QR code to read on your phone
We could not find any corresponding parameters, please add them to the properties table

RELATED WEBSITES

友情链接

Time of issue:2020-07-27 00:00:00
Online customer service
Customer service hotline
+86-023-67886928 +86-023-67886928
Service time:
8:30 - 17:30
Customer service group:
在线客服

地址版权

Time of issue:2019-05-10 00:00:00

© 2021 Chongqing Huapont Pharmaceutical Co., Ltd. All Rights Reserved.  渝ICP备2021007919号  1渝公网安备50011702500758号  Powered by:www.300.cn

地址版权手机

Time of issue:2019-05-10 00:00:00

© 2021 Chongqing Huapont Pharmaceutical Co., Ltd.

渝ICP备2021007919号  Powered by:www.300.cn

1渝公网安备50011702500758号